Methylation-based biological age and cardiotoxicity risk in breast cancer patients treated with trastuzumab.

ABSTRACT:

Background

Trastuzumab is an effective treatment for HER2-positive cancers that has known cardiotoxic properties. Discovering biomarkers that assess cardiotoxicity risk before trastuzumab therapy is essential for protecting the cardiovascular health of cancer patients.

Objective

To examine the associations between pre-treatment epigenetic age acceleration, circulating leukocyte composition, and candidate single nucleotide polymorphisms (SNPs) with cardiotoxicity risk in breast cancer patients receiving trastuzumab.

Methods

Among a retrospective cohort of HER2-positive breast cancer patients treated with trastuzumab at Moffitt Cancer Center, we profiled blood DNA methylation and genetic profiles. Epigenetic clocks and circulating leukocyte subsets were derived from Met

SUBMITTER: Mammadova J 

PROVIDER: S-EPMC12065287 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature